Navigation Links
Experimental Alzheimer's Drug Shows Promise
Date:4/17/2008

Analysis of early study found cognitive function improved in patients

THURSDAY, April 17 (HealthDay News) -- A new analysis of a study on an experimental Alzheimer's drug reinforces the notion that the compound is broadly effective at improving the cognitive function of mild to moderate Alzheimer's patients.

A second analysis of the trial on the medication, known as Dimebon, also reveals that by improving the Alzheimer's patients' ability to perform daily tasks, the drug shaves off almost an hour a day in the amount of time the average caregiver must attend to his or her patient.

The twin observations raise hope for a new and improved therapy to address both the symptoms and the underlying mechanisms driving a disease that the Alzheimer's Association says currently affects more than 5 million Americans.

"The broad context is that there are treatments available that treat Alzheimer's symptoms, but do not slow the disease down or prevent it," explained Steven H. Ferris, director of the Alzheimer's Disease Center at New York University. "So, we really need drugs that are more potent and safe and that actually slow the disease down."

"And this drug has that potential," he said. "It still needs more research -- which is going to happen. But, so far, it really looks like it might have a better effect than existing drugs and also a better side effect profile."

Ferris is expected to discuss the new research on Dimebon on Thursday at the American Academy of Neurology annual meeting, in Chicago.

He pointed out, however, that he played no role of any kind in initial analysis of a recently completed yearlong study that had looked into the drug's prospects.

Ferris describes his current connection to the Dimebon study as that of a paid "external scientific advisory board" member to drug maker Medivation Inc., engaged in helping the company interpret the findings to date while moving forward with future study plans for its drug. He has no equity in the company.

The original study -- funded by the San Francisco-based Medivation Inc. -- had been conducted in Russia, under American guidance and supervision.

The authors of that effort first released preliminary findings last June on the safety and effectiveness of the experimental drug among 183 mild to moderate Alzheimer's patients.

At the time, the researchers concluded that Dimebon helped boost patient memory and clinical function, while also improving the ability to think and engage in daily activities -- without prompting major side effects.

They noted that the new drug packed the symptom-fighting punch, in effect, of both an anticholinesterase drug (such as Aricept) and another class of medications known as glutamate antagonists. As well, the authors claimed that Dimebon also protected brain cells from Alzheimer-causing amyloid build-up, thereby defending against disease progression itself.

Ferris said that Thursday's presentation is essentially a "secondary look" at these initial conclusions.

The first finding is based on a number-crunching of cognition tests run at the 12-, 26-, 39- and 52-week study marks. The analysis revealed sweeping improvements in terms of memory (such as word recall, recognition, and instruction recollection); orientation; the ability to perform complex activities; and language comprehension.

The second finding -- based on the same tests -- observed that patients taking Dimebon were better able to take care of themselves in basic ways, such as being able to eat and prepare a meal, use the toilet, use the phone, read, use appliances, keep appointments, and hold a conversation.

As a result, the study authors said that caregivers saved 51 minutes a day on average in the time they spent caring for an Alzheimer's patient.

"What's new here is that we're looking in a more specific way at the nature of the drug's cognitive effect," he said. "To see whether it's narrow or broad. And what we found is that it's a broad effect. Virtually all of the health categories we looked at showed a significant treatment benefit, and the time spent by the family member having to deal with the patient was actually reduced."

Greg M. Cole, associate director of the Alzheimer's Disease Research Center at the UCLA David Geffen School of Medicine, said the new analyses appeared to be consistent with initial study findings. But he added that much more research is needed.

"We see that this drug improves patient outcome relative to taking nothing," he noted. "But the real question is how does Dimebon compare with the standard of care today? That's what remains to be seen."

More information

For additional information on current symptom treatment options for Alzheimer's, visit the Alzheimer's Association.



SOURCES: Steven H. Ferris, Ph.D., professor, psychiatry, New York University, and director, Alzheimer's Disease Center, New York University, New York City; Greg M. Cole, Ph.D., neuroscientist, Greater Los Angeles VA Healthcare System, and associate director, Alzheimer's Disease Research Center, UCLA David Geffen School of Medicine; April 17, 2008, presentation, American Academy of Neurology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental drug shows promise in treating certain lymphomas
2. Experimental Cancer Vaccines Show Promise
3. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
4. Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints
5. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
6. 52 minority scientists receive travel fellowships to Experimental Biology 2008
7. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
8. Experimental Vaccine Halts Prostate Cancer in Mice
9. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
10. Experimental Drug Fights Prostate Cancer
11. Experimental Drug Fails Against Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Alzheimer's Drug Shows Promise
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology: